 |
|
|
|
February 2001 Cover
|
|
The U.S. Food and Drug Administration (FDA) has approved a combination drug for the treatment of HIV, but the agency has warned that about 5 percent of patients trying the pill could undergo a severe, possibly fatal
if untreated, allergic reaction. Called Trizivir, Glaxo Wellcome's combination of AZT, 3TC, and Ziagen (abacavir) reduces the number of pills needed in an HIV regimen from four to two. Trizivir will reach the market in December, according to Glaxo, at a price of $26.60 per day. The FDA's warning stems from the fact that about 5 percent of
people taking Ziagen experience serious allergic reactions, so patients trying the new drug combination also have that same risk.
Editor's Note: from The Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
